PolyNovo Limited
(ASX:PNV) has announced it has partnered with Professor Toby Coates and A/Professor John Greenwood AM to develop an alternative to Islet Cell Transplantation for diabetes management.
The research aims to uncover whether islet cell transplantation into the skin verses the liver of a Type 1 diabetes patient is a viable alternative treatment method.
If the research is successful, it has the potential for recipients to no longer require regular insulin injections.
Type 1 diabetes currently affects over 120,000 Australians and is a major cause of death and disability in young Australians.
PolyNovo Limited reported a net loss of $2.3 million at 31 December 2015.